The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment
Elizabeth Hardaker(AstraZeneca (United Kingdom)), Steven Fawell(AstraZeneca (Brazil)), Larissa S. Carnevalli(AstraZeneca (Singapore)), Serge Y. Fuchs(University of Pennsylvania), Pei‐Jen Lou(National Taiwan University), Ankur Karmokar(Jazz Pharmaceuticals (United States)), Gemma N. Jones(AstraZeneca (United Kingdom)), Şehmus Tohumeken(Friedrich-Alexander-Universität Erlangen-Nürnberg), David G. Campbell(University of Dundee), Scott Hoffmann(AstraZeneca (United Kingdom)), Sonia Iyer(Whitehead Institute for Biomedical Research), Marta Milo(AstraZeneca (Brazil)), Shaan Gill(AstraZeneca (United Kingdom)), Mimi Mai(AstraZeneca (Netherlands)), Anisha Solanki(AstraZeneca (United Kingdom)), Gozde Kar(Wellcome Sanger Institute), Elaine Cadogan(AstraZeneca (Singapore)), Benjamin Phillips(AstraZeneca (United Kingdom)), Tamara Baker(AstraZeneca (United Kingdom)), J. Carl Barrett(National Institute of Environmental Health Sciences), Adina Hughes(AstraZeneca (United Kingdom)), Umamaheswar Duvvuri(City University of New York), Daniel Sutton(AstraZeneca (United Kingdom)), Gilberto S. Almeida(AstraZeneca (United Kingdom)), Henderson Fryer(AstraZeneca (Netherlands)), Abdel Wahad Bidar(AstraZeneca (Netherlands)), Emilio Sanseviero(The Wistar Institute), Carla P. Martins(AstraZeneca (United Kingdom)), Carolyn S.P. Lam(University of Glasgow), Zena Wilson(AstraZeneca (United Kingdom)), Michael Surace(AstraZeneca (Netherlands)), Lynet Nyoni(AstraZeneca (United Kingdom)), Kathy Mulgrew(AstraZeneca (Netherlands)), Łukasz Magiera(AstraZeneca (United Kingdom)), Fernando J. Calero‐Nieto(Wellcome/MRC Cambridge Stem Cell Institute), Zainab Ramlaoui(AstraZeneca (Netherlands)), Sara Talbot(AstraZeneca (United Kingdom)), Melonie A. Nance(Anna Needs Neuroblastoma Answers), Nathan Standifer(Serimmune (United States)), Andrew J. Pierce(Ouachita Baptist University), Alison Peter(AstraZeneca (United Kingdom)), Joseph F. Boland(AstraZeneca (Netherlands)), Susan E Critichlow(AstraZeneca (United Kingdom)), Devon K. Taylor(AstraZeneca (Netherlands)), Arsène‐Bienvenu Loembé(AstraZeneca (Netherlands)), Matthew King(Atrium Health Wake Forest Baptist), Chrysis Michaloglou(AstraZeneca (United Kingdom)), Carlos Gomez‐Roca(Université Fédérale de Toulouse Midi-Pyrénées), Mostafa Ali(AstraZeneca (Netherlands)), Ricardo J. Miragaia(Wellcome Sanger Institute)
Cited by 62
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Journal of Heart Failure|2022|2.1k
The Global Health and Economic Burden of Hospitalizations for Heart Failure
|Journal of the American College of Cardiology|2014|2k